Filing Details

Accession Number:
0001209191-22-001328
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-04 21:33:55
Reporting Period:
2022-01-03
Accepted Time:
2022-01-04 21:33:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
879407 Arrowhead Pharmaceuticals Inc. ARWR Pharmaceutical Preparations (2834) 460408024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242615 Y Adeoye Olukotun 177 E Colorado Blvd
Ste 700
Pasadena CA 91105
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-01-03 1,890 $64.26 7,110 No 4 S Direct
Common Stock Disposition 2022-01-03 1,916 $65.04 5,194 No 4 S Direct
Common Stock Disposition 2022-01-03 244 $66.25 4,950 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuantto a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to$64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.74 to$65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4